P137 5 year budget impact analysis of CT-P13 (Infliximab) for the treatment of Crohn's Disease in UK, Italy and France
J. Kim1, J. An Hong*1, A. Kudrin2
1CELLTRION HEALTHCARE, Medical Communications, Incheon, South Korea, 2CELLTRION, Product development Div. , Incheon, South Korea
CT-P13 (infliximab) has been approved for the treatment of inflammatory autoimmune disorders including Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis. Recent studies have shown considerable potential savings through the use of biosimilars for the investigated classes of biological drugs, for instance, the first generation biosimilar filgrastim which decreased the treatment cost by its introduction in oncology field. The market growth of comparator infliximab was reported to grow since the product introduction on EU market.
We aimed to evaluate the cost benefits of the introduction of CT-P13 (infliximab) in treatment of Crohn's disease from the payer and the patient perspectives by using an Excel based budget-impact model over a five-year time horizon. The model calculated patients eligible for infliximab treatment based on the prevalence of Crohn's disease, total population, and annual population growth rate in 3 major EU countries; UK, Italy, and France. The acquisition cost of comparator infliximab was assumed not to change after the introduction of biosimilar mAb. The price of the CT-P13 (infliximab) is currently unknown, therefore three different discount scenarios (10%, 20%, and 30%) were applied to evaluate the budget impact. Market uptake growth was also varied in each of the scenarios at 20%, 30%, and 40%, respectively. The market share was assumed to be 25% in the first year in all scenarios
The total budget saving for the 10% price discount scenario for all three countries throughout the years 2015, 2016, 2017, 2018, and 2019 was 10,210,000, 12,240,000, 14,730,000, 17,670,000, and 21,220,000 euros, respectively. The total budget saving for the 20% price discount scenario throughout the years 2015, 2016, 2017, 2018, and 2019 was 20,420,000,26,560,000, 34,570,000, 44,930,000, and 58,440,000 euros, respectively. The total budget saving for the 30% price discount scenario across the years 2015, 2016, 2017, 2018, and 2019 was 30,640,000, 42,900,000, 60,120,000 84,180,000, and 117,890,000 euros, respectively. The total budget saving over the five year period (2015 -2019) for all three countries was 76,070,000, 184,920,000, and 335,730,000 euros for the 10%, 20%, and 30% price discount scenarios, respectively.
The introduction of the CT-P13 (infliximab) as a treatment option for patients with Crohn's disease could achieve substantial cost savings. In the scenarios tested, the total 5 year saving across UK, Italy and France ranged from 76 million to 336 million euros.